tetano
Editor, Senior Moderator
Crit Rev Clin Lab Sci
. 2020 Jun 5;1-11.
doi: 10.1080/10408363.2020.1770685. Online ahead of print.
Biomarkers Associated With COVID-19 Disease Progression
Giovanni Ponti[SUP] 1 [/SUP], Monia Maccaferri[SUP] 2 [/SUP], Cristel Ruini[SUP] 1 3 [/SUP], Aldo Tomasi[SUP] 1 [/SUP], Tomris Ozben[SUP] 4 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is a scientific, medical, and social challenge. The complexity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is centered on the unpredictable clinical course of the disease that can rapidly develop, causing severe and deadly complications. The identification of effective laboratory biomarkers able to classify patients based on their risk is imperative in being able to guarantee prompt treatment. The analysis of recently published studies highlights the role of systemic vasculitis and cytokine mediated coagulation disorders as the principal actors of multi organ failure in patients with severe COVID-19 complications. The following biomarkers have been identified: hematological (lymphocyte count, neutrophil count, neutrophil-lymphocyte ratio (NLR)), inflammatory (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin (PCT)), immunological (interleukin (IL)-6 and biochemical (D-dimer, troponin, creatine kinase (CK), aspartate aminotransferase (AST)), especially those related to coagulation cascades in disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS). New laboratory biomarkers could be identified through the accurate analysis of multicentric case series; in particular, homocysteine and angiotensin II could play a significant role.
Keywords: COVID-19; biochemical biomarkers; biomarkers of disease progression; hematological biomarkers; immunological biomarkers; inflammatory biomarkers; neutrophil–lymphocyte ratio (NLR).
. 2020 Jun 5;1-11.
doi: 10.1080/10408363.2020.1770685. Online ahead of print.
Biomarkers Associated With COVID-19 Disease Progression
Giovanni Ponti[SUP] 1 [/SUP], Monia Maccaferri[SUP] 2 [/SUP], Cristel Ruini[SUP] 1 3 [/SUP], Aldo Tomasi[SUP] 1 [/SUP], Tomris Ozben[SUP] 4 [/SUP]
Affiliations
- PMID: 32503382
- DOI: 10.1080/10408363.2020.1770685
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is a scientific, medical, and social challenge. The complexity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is centered on the unpredictable clinical course of the disease that can rapidly develop, causing severe and deadly complications. The identification of effective laboratory biomarkers able to classify patients based on their risk is imperative in being able to guarantee prompt treatment. The analysis of recently published studies highlights the role of systemic vasculitis and cytokine mediated coagulation disorders as the principal actors of multi organ failure in patients with severe COVID-19 complications. The following biomarkers have been identified: hematological (lymphocyte count, neutrophil count, neutrophil-lymphocyte ratio (NLR)), inflammatory (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin (PCT)), immunological (interleukin (IL)-6 and biochemical (D-dimer, troponin, creatine kinase (CK), aspartate aminotransferase (AST)), especially those related to coagulation cascades in disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS). New laboratory biomarkers could be identified through the accurate analysis of multicentric case series; in particular, homocysteine and angiotensin II could play a significant role.
Keywords: COVID-19; biochemical biomarkers; biomarkers of disease progression; hematological biomarkers; immunological biomarkers; inflammatory biomarkers; neutrophil–lymphocyte ratio (NLR).